Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the entire transmembrane and cytoplasmic domains of murine VEGFR-2 (Rahimi et al.,
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Abstract:
Activation of vascular endothelial growth factor receptor-2 (VEGFR-2) plays a critical role in vasculogenesis and angiogenesis. However, the mechanism by which VEGFR-2 activation elicits these cellular events is not fully understood. We recently constructed a chimeric receptor containing the extracellular domain of human CSF-1R/c-fms, fused with the entire transmembrane and cytoplasmic domains of murine VEGFR-2 (Rahimi et al., JBC 275: 16986-16992, 2000) . In this study we used VEGFR-2 chimera severe deficiency in vessel formation (1) . Furthermore, introduction of either a neutralizing antibody against VEGF or the dominant negative form of VEGFR-2 was able to block angiogenesis (2, 3) . On the other hand, VEGFR-1 activation alone appears to play a less significant role in these cellular processes (4, 5, 6) .
The mechanism by which VEGFR-2 activation evokes angiogenesis is not well understood. It is presumed that these events are initiated by binding of VEGF to VEGFR-2 leading to tyrosine phosphorylation of the dimerized VEGFR-2 and subsequent phosphorylation of SH2-containing intracellular signaling proteins including phospholipase C-γ1 (PLC-γ1), Src family tyrosine kinases, and phosphatidylinositol-3 kinase (PI-3 kinase), adaptor molecules, SHC, NCK and Ras GTPase-activating protein (7) (8) (9) (10) . The contributions of individual signaling molecules to various aspects of angiogenesis and the tyrosine sites on VEGFR-2 that potentially mediate their recruitment and activation have not been fully investigated. Moreover, the data presented in the literature is often inconsistent. Waltenberger et al., (1994) , Abedi and Zachary (1997) and Takahashi et al., (1997) have suggested that stimulation of endothelial cells with VEGF results in no PI-3 kinase activation (7, 8, 11) , while others have shown that VEGFR-2 activation does indeed result in PI-3 kinase stimulation, which may stimulate endothelial cell growth and survival (12, 13 Na3VO4) and lysed in lysis (EB) buffer (10mM Tris-HCl, 10% glycerol, pH 7.4, 5mM EDTA, 50mM NaCl, 50mM NaF, 1% Triton X-100, 1mM
phenylmethylsulfonyl fluoride, 2mM Na 3 VO 4 , and 20(µg/ml aprotinin). Proteins were immunoprecipitated by using appropriate antibodies. Immunocomplexes were bound to protein A Sepharose, and washed three times with 1.0 ml of EB.
Immunoprecipitates were resolved on a SDS-PAGE gel, and the proteins were Because VEGFR-2 activity is associated with endothelial cell migration Previously it has been demonstrated that the SH2 domains of p85 are required for complex formation between p85 and other tyrosine phosphorylated proteins (19) . To test the ability of the p85 SH2 domains to bind CKR, cell lysates derived from PAE cells expressing CKR were examined for their capacity to bind a GST-(N terminus) SH2 and GST-(C terminus) SH2. The complexed proteins were eluted, and CKR was detected by immunobloting with an anti-VEGFR-2
antibody. In a lysate of CSF-1 stimulated CKR/PAE cells, both GST-SH2-NH2
and GST-SH2-COOH of p85 formed stable complexes with CKR but not in nonstimulated cells. In contrast, incubation of the protein extracts with GST alone did result in any binding to CKR ( Figure 3D ). These data show that p85 binds to 
PI-3 kinase/S6 kinase activation is required for CKR-mediated Cell growth.
To evaluate the importance of PI-3 kinase further in CKR-mediated cell growth, we used an additional approach by using wortmannin, a specific inhibitor of PI-3 kinase (20) . To this end, PAE cells expressing CKR, were pre-treated with different concentrations of wortmannin, stimulated with CSF-1 and cells subjected to a proliferation assay. Figure 5A shows that pretreatment of cells with wortmannin effectively inhibits CSF-1 stimulated cell growth in a dose dependent manner. This result combined with the site-directed mutagenesis data ( Figure 2A ) strongly suggests that PI-3 kinase activation play a key role in VEGFR-2 stimulated endothelial cell proliferation.
To further identify and define the involvement of PI-3 kinase-regulated pathways in this system in particular, endothelial cell proliferation, we investigated the role of p70 S6 kinase, a downstream target of PI-3 kinase. For this reason, serum-starved PAE cells expressing CKR and tyrosine mutant CKRs were stimulated with CSF-1 and total cell lysates were subjected to an antiphospho-S6 kinase Western blot analysis. The results showed that CKR is able to stimulate phosphorylation of S6 kinase in a CSF-1 dependent manner.
CKR/F799 and CKR/F1173 were partially able to stimulate S6 kinase activation, whereas CKR/F2 complelty failed to stimulate S6 kinase phosphorylation in the same assay condition ( Figure 5B ). To establish whether S6 kinase activity is required for CKR-mediated PAE cell proliferation, serum-starved CKR/PAE cells were pretreated with rapamycin, an inhibitor of RAFT1 and as a consequence downstream target of p70 S6 kinase (21) . The result showed that rapamycin effectively blocks CKR stimulated PAE cell growth ( Figure 5C ), suggesting that PI-3 kinase/S6 kinase pathway is responsible for VEGFR-2 mediated endothelial cell growth. Notably, treatment of PAE cells with rapamycin without CSF-1 stimulation also partly reduced basal growth of PAE cells, suggesting that S6 kinase activity is required for normal growth of PAE cells. This effect of rapamycin does not appear due to high concentration of rapamycin, since at 10-50 ng/ml it inhibited phosphorylation of S6 kinase approximately by 60 to 90%, respectively (data not shown). As it is true for most of pharmacological agents, rapamycin may also effect activation of signaling molecules other than S6 kinase that might be involved in growth of PAE cells.
Activation Ras/MAPK pathway is not required for CKR-mediated cell growth
Next we tested the capability of these mutant receptors to stimulate MAPK activation. For this purpose, PAE cells expressing CKR and mutant CKRs were serum-starved, stimulated with CSF-1, lysed and equal amount of proteins of total cell lysates were subjected to Western blot analysis using anti-phospho-MAPK antibody. The result shows that mutant CKRs are able to stimulate MAPK with equal ability as compared to wild type CKR ( Figure 6A ). In addition, phosphorylation of MAPK by mutant CKRs was not effected at least up to 30 minutes of stimulation with CSF-1 (data not shown).
To test whether MAPK activation plays a role in CKR-mediated cell growth, we subjected PAE cells expressing CKR to proliferation assay in which cells were pre-treated with PD98059, a potent and selective inhibitor of MAP kinase inhibitor (22) . As Figure 6C shows, PD98059 treatment of PAE cells expressing CKR did not inhibit CKR mediated cell proliferation. Collectively, these data suggest that although CKR activation results in robust MAPK activation, its activity may not be required for CKR-mediated cell growth in PAE cells. To assure that PD98059 at the concentration used in proliferation assay indeed is inhibiting MAP kinase activation, we measured MAP kinase phosphorylation. As Figure 6D shows pre-treatment of cells with PD98059 (50 µM) effectively inhibited MAP kinase phosphorylation. Since, MAPK activation is mainly mediated by Ras finally we assessed its role in this process. For this purpose, we transiently over-expressed N17ras in CKR/PAE cells by a retrovirus system and subjected them to proliferation assay. The result showed that expression of dominant negative form of ras (N17 ras) only had a minor effect on the CSF-1 stimulated cell growth ( Figure 7A ). Figure 7B shows expression of N17 ras in CKR/PAE cells. All together, these results suggest that activation of Ras/MAPK pathway is not required for VEGFR-2 mediated PAE cell proliferation. A number of groups have investigated the role PLCγ1 in VEGF-dependent signal relay. The initial observations suggested that PLCγ activation is increased in a VEGF stimulated cells (8, 9, 26) . Subsequent study showed that tyrosine 951 on the human VEGFR-2 is a major binding site for PLCγ1 (27) . In agreement with
Discussion
this study our results demonstrate that tyrosines 799 and 1173 of mouse VEGFR-2 are not required for PLCγ1 activation and likely tyrosine 951 is the primary binding site for PLCγ1. In addition, our results demonstrate that although PLCγ1 is activated by VEGFR-2, its activation is not required for VEGF-mediated endothelial cell growth. Activation of PLCγ1 has been shown to stimulate cell growth and migration in variety of cellular systems, however its role in VEGFR-2 mediated signal transduction and endothelial cell function is largely unknown.
Recently, it has been suggested that inhibition of PLCγ1 by pharmacological mean blocks VEGF-stimulated sinusoidal endothelial cell growth (28) . Since sinusoidal cells express both VEGFR-1 and VEGFR-2, it is difficult to judge the contributions of each receptor to the observed PLCγ1 activation.
Thus, it seems that tyrosines 799 and 1173 are novel p85 docking sites for p85 of PI 3-kinase, although they may represent a low affinity binding sites for P85. Amino acids residues surrounding tyrosine 799 (YLSIVM) and 1173
binding sites (29, 30) . While, it is generally believed that SH2 domains of p85 preferentially bind to receptor tyrosine kinases through this motif, other binding sites for p85 of PI -3 kinase have been described. For instance, p85 binding to hepatocyte growth factor receptor family including c-Met, c-Ron and c-Sea is mediated by the YVHV (31, 32) . Similarly, it has been demonstrated that amino acids YVNA on VEGFR-1 is binding site for p85 (33) .
Until now, little evidence existed for the involvement of PI-3 kinase in VEGFR-2 mediated signal transduction and angiogenesis. The possibility that PI-3 kinase may be involved could be inferred only from very indirect evidence.
Initial studies about the activation of PI-3 kinase by VEGFR-2 suggested that PI-3 kinase is not activated by VEGFR-2 stimulation (7, 8, 11) . However, subsequent studies suggested that VEGF stimulation of endothelial cells results in activation of PI-3 kinase and its activation may promote endothelial cell survival (12, 13) . were infected with retrovirus containing N 17 ras, as described in part A, however cells were lysed and subjected to western blot analysis by using anti-Ras antibody (B).
